Target intelligence / Profile preview

System-level multicellular environment

Molecular classification
Other
01

Overview

The system-level multicellular environment refers to the complex, integrated network of diverse cell types—including malignant cells, immune cells, fibroblasts, and endothelial cells—and non-cellular components like the extracellular matrix (ECM) that surround and interact with diseased tissues. Rather than a single molecular target, it represents a biological ecosystem where reciprocal signaling between cells dictates disease progression, immune evasion, and therapeutic resistance (Source: NIH National Cancer Institute). In oncology, this is most commonly characterized as the tumor microenvironment (TME), which is actively remodeled by cancer cells to support growth and suppress anti-tumor immunity (Source: Nature Reviews Cancer). Therapeutic strategies targeting this environment often focus on 'reprogramming' the ecosystem, such as using checkpoint inhibitors to reactivate exhausted T cells or anti-angiogenic agents to normalize the vasculature (Source: Nature Reviews Drug Discovery). Understanding the system-level environment is crucial for developing combination therapies that address the collective behavior of the multicellular unit rather than just the primary diseased cell (Source: PubMed/PMC).

Other names
Tumor microenvironmentTMEMulticellular ecosystemTissue microenvironmentCellular nicheStroma
02

Mechanism of action

Modulation of the multicellular ecosystem through immune checkpoint inhibition, inhibition of angiogenesis, depletion of immunosuppressive stromal cells, or alteration of the extracellular matrix to enhance drug delivery and immune infiltration.

03

Biological functions

Cell-cell communicationImmune responseSignal transductionHomeostasisTissue remodelingAngiogenesis
04

Disease associations

CancerInflammationFibrosisAutoimmune diseaseNeurodegenerative disease
05

Safety considerations

Immune-related adverse events (irAEs)Cytokine release syndrome (CRS)Systemic toxicity due to loss of tissue homeostasisImpaired wound healingOff-target effects on healthy tissue microenvironments
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

PD-L1 expressionTumor-infiltrating lymphocytes (TILs)Tumor mutational burden (TMB)Cytokine profiles (e.g., IL-6, IFN-gamma)Gene expression signatures (e.g., IFN-gamma signature)

Beyond the preview

Go deeper on System-level multicellular environment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on System-level multicellular environment.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call